An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

5500

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer, Early Breast Cancer

Interventions

DRUG: Camizestrant
DRUG: Tamoxifen
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Exemestane
DRUG: Abemaciclib

Sponsor

AstraZeneca

Collaborators

[object Object]